FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382583746> ?p ?o ?g. }

• W4382583746 abstract "Suppressive antibiotic therapy (SAT) is a strategy to alleviate symptoms and/or to reduce the progression of an infection when other treatment options cannot be used. Dalbavancin, due to its prolonged half-life, enables (bi) weekly dosing. Here, we report our multicenter real-life clinical experience with dalbavancin used as SAT in patients with prosthetic joint or vascular infections. Medical records of all adult patients with documented vascular or orthopedic chronic prosthetic infections, who received dalbavancin as SAT between 2016 and 2018 from four Spanish hospitals were reviewed for inclusion. Descriptive analysis of demographic characteristics, Charlson Comorbidity index, Barthel index, isolated pathogens and indication, concomitant antibiotic use, adverse events, and clinical outcome of SAT were performed. Eight patients were eligible for inclusion, where six patients had prosthetic vascular infections (aortic valve) and two patients had knee prosthetic joint infections. The most common pathogens were methicillin-susceptible Staphylococcus aureus and Enterococcus faecium . All patients had a history of prior antibiotic treatment for the prosthetic infection [median duration of antibiotic days 125 days (IQR, 28–203 days)]. The median number of dalbavancin doses was 29 (IQR, 9–61) and concomitant antibiotic use ( n = 5, 62.5%). Clinical success was reported in 75% ( n = 6) of patients. Adverse events were reported in two patients (mild renal and hepatic impairment). The median estimated cost savings due to the avoided hospital days was €60185 (IQR, 19,916–94984) per patient. Despite the limitations of our study, this preliminary data provides valuable insight to support further evaluation of dalbavancin for SAT in patients with prosthetic infections in the outpatient setting when alternative treatments are not feasible." @default.
• W4382583746 created "2023-06-30" @default.
• W4382583746 creator A5004201730 @default.
• W4382583746 creator A5033544235 @default.
• W4382583746 creator A5043218702 @default.
• W4382583746 creator A5047814756 @default.
• W4382583746 creator A5066362911 @default.
• W4382583746 creator A5070157012 @default.
• W4382583746 creator A5076493491 @default.
• W4382583746 date "2023-06-28" @default.
• W4382583746 modified "2023-10-18" @default.
• W4382583746 title "Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety" @default.
• W4382583746 cites W1983255179 @default.
• W4382583746 cites W1986644134 @default.
• W4382583746 cites W2020861729 @default.
• W4382583746 cites W2035839449 @default.
• W4382583746 cites W2051239218 @default.
• W4382583746 cites W2092084708 @default.
• W4382583746 cites W2099018662 @default.
• W4382583746 cites W2126890410 @default.
• W4382583746 cites W2128429789 @default.
• W4382583746 cites W2171117330 @default.
• W4382583746 cites W2175925164 @default.
• W4382583746 cites W2415850832 @default.
• W4382583746 cites W2556179740 @default.
• W4382583746 cites W2587803266 @default.
• W4382583746 cites W2605261705 @default.
• W4382583746 cites W2744274169 @default.
• W4382583746 cites W2768209410 @default.
• W4382583746 cites W2806260174 @default.
• W4382583746 cites W2903263510 @default.
• W4382583746 cites W2916793830 @default.
• W4382583746 cites W2938617289 @default.
• W4382583746 cites W2944828204 @default.
• W4382583746 cites W2975563029 @default.
• W4382583746 cites W2985143789 @default.
• W4382583746 cites W3037063452 @default.
• W4382583746 cites W3088891968 @default.
• W4382583746 cites W3126032939 @default.
• W4382583746 cites W3159238143 @default.
• W4382583746 cites W4307228603 @default.
• W4382583746 doi "https://doi.org/10.3389/fphar.2023.1185602" @default.
• W4382583746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37448966" @default.
• W4382583746 hasPublicationYear "2023" @default.
• W4382583746 type Work @default.
• W4382583746 citedByCount "1" @default.
• W4382583746 crossrefType "journal-article" @default.
• W4382583746 hasAuthorship W4382583746A5004201730 @default.
• W4382583746 hasAuthorship W4382583746A5033544235 @default.
• W4382583746 hasAuthorship W4382583746A5043218702 @default.
• W4382583746 hasAuthorship W4382583746A5047814756 @default.
• W4382583746 hasAuthorship W4382583746A5066362911 @default.
• W4382583746 hasAuthorship W4382583746A5070157012 @default.
• W4382583746 hasAuthorship W4382583746A5076493491 @default.
• W4382583746 hasBestOaLocation W43825837461 @default.
• W4382583746 hasConcept C126322002 @default.
• W4382583746 hasConcept C141071460 @default.
• W4382583746 hasConcept C197934379 @default.
• W4382583746 hasConcept C2776703206 @default.
• W4382583746 hasConcept C2777288759 @default.
• W4382583746 hasConcept C2777677444 @default.
• W4382583746 hasConcept C2778980435 @default.
• W4382583746 hasConcept C2779384505 @default.
• W4382583746 hasConcept C2779489039 @default.
• W4382583746 hasConcept C2781336494 @default.
• W4382583746 hasConcept C501593827 @default.
• W4382583746 hasConcept C523546767 @default.
• W4382583746 hasConcept C54355233 @default.
• W4382583746 hasConcept C71924100 @default.
• W4382583746 hasConcept C86803240 @default.
• W4382583746 hasConcept C89423630 @default.
• W4382583746 hasConceptScore W4382583746C126322002 @default.
• W4382583746 hasConceptScore W4382583746C141071460 @default.
• W4382583746 hasConceptScore W4382583746C197934379 @default.
• W4382583746 hasConceptScore W4382583746C2776703206 @default.
• W4382583746 hasConceptScore W4382583746C2777288759 @default.
• W4382583746 hasConceptScore W4382583746C2777677444 @default.
• W4382583746 hasConceptScore W4382583746C2778980435 @default.
• W4382583746 hasConceptScore W4382583746C2779384505 @default.
• W4382583746 hasConceptScore W4382583746C2779489039 @default.
• W4382583746 hasConceptScore W4382583746C2781336494 @default.
• W4382583746 hasConceptScore W4382583746C501593827 @default.
• W4382583746 hasConceptScore W4382583746C523546767 @default.
• W4382583746 hasConceptScore W4382583746C54355233 @default.
• W4382583746 hasConceptScore W4382583746C71924100 @default.
• W4382583746 hasConceptScore W4382583746C86803240 @default.
• W4382583746 hasConceptScore W4382583746C89423630 @default.
• W4382583746 hasLocation W43825837461 @default.
• W4382583746 hasLocation W43825837462 @default.
• W4382583746 hasLocation W43825837463 @default.
• W4382583746 hasOpenAccess W4382583746 @default.
• W4382583746 hasPrimaryLocation W43825837461 @default.
• W4382583746 hasRelatedWork W2014158951 @default.
• W4382583746 hasRelatedWork W2378033034 @default.
• W4382583746 hasRelatedWork W2756630929 @default.
• W4382583746 hasRelatedWork W2811370978 @default.
• W4382583746 hasRelatedWork W2912936374 @default.
• W4382583746 hasRelatedWork W4200542296 @default.
• W4382583746 hasRelatedWork W4220709455 @default.
• W4382583746 hasRelatedWork W43079460 @default.

• next